Table 1.
Patient and tumour characteristics
| Variable | Number | |
| Gender | Male | 22 (47%) |
| Female | 25 (53%) | |
| Age | Range (median) | 23–80 (54) |
| <50 | 17 (36%) | |
| 50–59 | 14 (30%) | |
| 60–69 | 12 (26%) | |
| >69 | 4 (9%) | |
| Location of primary | Midgut | 21 (45%) |
| Pancreas | 15 (32%) | |
| Hindgut | 2 (4%) | |
| Lung | 3 (6%) | |
| Unknown | 2 (4%) | |
| Other (neuroectodermal and MTC) | 4 (9%) | |
| Tumour Grade | Grade 1 | 14 (30%) |
| Grade 2 | 17 (36%) | |
| Grade 3 | 4 (9%) | |
| Unavailable | 12 (26%) | |
| Hepatic tumour load (% of liver with metastatic involvement) | 0% | 5 (11%) |
| 0–25% | 13 (29%) | |
| 25–50% | 18 (40%) | |
| >50% | 9 (20%) | |
| Presence of bone metastases | Yes | 19 (42%) |
| No | 26 (58%) | |
| Previous treatments | SSAs | 40 (85%) |
| Resection of primary | 22 (47%) | |
| Chemotherapy | 19 (40%) | |
| Radiotherapy | 8 (17%) | |
| Liver targeted treatments | 15 (32% | |
| Interferon/sunitinib/everolimus | 1 (2%) |
MTC, medullary thyroid cancer; SSAs, somatostatin analogues.